Advantis Medical Imaging receives its 2nd FDA clearance for its brain & prostate MRI software platform

ATHENS, Greece, April 12, 2023 -- Advantis Medical Imaging, a leading medical software development company, announced today that the U.S. Food and Drug Administration (FDA) has granted clearance to Advantis Platform, its advanced Brain and Prostate MRI Analysis Software, for commercial distribution.

This is the second FDA clearance for the company following its first clearance in 2021 for the brain MRI solution traded under the name Brainance MD. After integrating its primary brain solution under the newly launched umbrella suite Advantis Platform, the company expanded its software suite capabilities by adding a second module for the processing and visualization of multiparametric prostate MRI exams.

The American Cancer Society estimates 288,300 new prostate cancer cases in the United States for 2023. While 1 man in 8 will be diagnosed with prostate cancer during his lifetime and the shortage of trained radiologists is growing on a yearly basis, the need for data-driven, accessible, and automated tools in today’s modern radiology departments is considered more essential than ever.

Advantis Platform comes with an upgraded feature set to improve the processing and reporting of brain and prostate MRI exam analysis in terms of quality and speed. By offering semi-automated and automated processing pipelines to clinicians, providing the required visibility to all processing workflows and avoiding black-box approaches, the platform assists clinicians to extract clinically meaningful quantitative information from the MRI examination in less time. In the meantime, the pure web-nature of Advantis Platform and its Software-as-a-Service distribution approach make it an easily accessible tool for any type and size of healthcare organization.

"We remain committed to delivering innovative medical imaging software solutions that address actual clinical questions and serve the demanding needs of modern radiology teams," said Paris Ziogkas, CEO of Advantis Medical Imaging. "This FDA clearance is a major milestone for our company and represents the culmination of years of hard work and dedication by our team of talented engineers and medical professionals. We are excited to make this cutting-edge software available to clinicians and researchers in the US, assisting them to focus on clinical findings and save valuable time."

"We are thrilled to see Advantis Platform with expanded organ and processing capabilities to be used in clinical practice." said Zoi Giavri, Chief Product Officer of Advantis Medical Imaging. "This latest FDA clearance is a testament to our commitment to delivering innovative solutions that streamline workflows and provide clinicians with reliable, accessible and efficient software tools. Our recent integration of the multiparametric Prostate MRI module in our software suite, Advantis Platform, complements the existing brain MRI module, while both of them enable healthcare professionals to more easily extract meaningful information from MRIs. Advantis Platform comes with an upgraded feature set including a standardized reporting tool leading to a more data-driven and efficient communication of results to the referring physicians."